NEW
YORK, Nov. 4, 2024 /PRNewswire/ -- The Gross Law
Firm issues the following notice to shareholders of Edwards
Lifesciences Corporation (NYSE: EW).
Shareholders who purchased shares of EW during the class period
listed are encouraged to contact the firm regarding possible lead
plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=110313&from=4
CLASS PERIOD: February 6,
2024 to July 24, 2024
ALLEGATIONS: According to the complaint, defendants
provided investors with material information concerning Edwards'
expected revenue for the fiscal year 2024, particularly as it
related to the growth of the Company's core product, Transcatheter
Aortic Valve Replacement ("TAVR"). Defendants' statements included,
among other things, strong commitment to the TAVR platform,
confidence in the Company's ability to capitalize on a subset of
untreated patients through scaling of its various patient
activation activities, and continued claims of significant demand
in allegedly lower-penetrated markets. On
July 24, 2024, Edwards unveiled
below-expectation financial results for the second quarter of
fiscal 2024 and, in particular, slashed its revenue guidance for
the TAVR platform for the full fiscal year 2024. The Company
attributed the TAVR setback on the "continued growth and expansion
of structural heart therapies … [which] put pressure on hospital
workflows." Investors understood this to mean that developments in
new procedures, including defendant's own Transcatheter Mitral and
Tricuspid Therapies ("TMTT"), put significant strain on hospital
structural heart teams such that they were underutilizing TAVR,
despite the Company's continued claim of a significantly
undertreated patient population. Moreover, the Company announced
three acquisitions during the second quarter designed to embolden
their treatments alternative to TAVR, suggesting further that the
company was aware of the potential for the TAVR platform's
decelerated growth. Investors and analysts reacted
immediately to Edwards' revelations. The price of Edwards' common
stock declined dramatically. From a closing market price of
$86.95 per share on July 24, 2024, Edwards' stock price fell to
$59.70 per share on July 25, 2024, a decline of about 31.34% in the
span of just a single day.
DEADLINE: December 13, 2024
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=110313&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of EW during the timeframe listed
above, you will be enrolled in a portfolio monitoring software to
provide you with status updates throughout the lifecycle of the
case. The deadline to seek to be a lead plaintiff is December 13, 2024. There is no cost or obligation
to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-notifies-edwards-lifesciences-corporation-investors-of-a-class-action-lawsuit-and-upcoming-deadline--ew-302294587.html
SOURCE The Gross Law Firm